Premium
Metabolomic Profile of Serum 25‐Hydroxy‐Vitamin D
Author(s) -
Nelson Shakira M,
Anic Gabriella M,
Panagiotou Orestis A,
Mondul Alison,
Weinstein Stephanie J,
Albanes Demetrius
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.918.3
Subject(s) - vitamin d and neurology , metabolite , metabolomics , medicine , prostate cancer , vitamin , endocrinology , cancer prevention , cancer , physiology , chemistry , chromatography
The role of vitamin D in human health has been studied using a variety of approaches. In laboratory studies, the active form of vitamin D, 1,25(OH) 2 D 3 has been shown to play a significant role in reducing autoimmune diseases, such as diabetes. In epidemiological studies, vitamin D has been associated with risk for some cancers but not others. For example, fairly consistent inverse (i.e., protective) associations with circulating 25‐hydroxy‐vitamin D (25(OH)D) have been observed for colorectal cancers, while direct (i.e., adverse) associations have been seen in prostate cancer studies. In order to gain a more comprehensive biological understanding of vitamin D associations with cancers and other health outcomes, we utilized a metabolomics approach to identify metabolites associated with serum 25(OH)D. Over 900 metabolites were measured from fasting blood samples collected at study entry between 1985 and 1988 in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention (ATBC) Study, a cohort of Finnish male smokers ages 50–69 years. Baseline serum 25(OH)D was measured in 392 men using radioimmunoassay, chemiluminescence assays, and OCTEIA direct enzyme‐linked immunosorbent assay kits. Metabolites were profiled using ultrahigh performance liquid chromatography/mass spectroscopy and gas chromatography/mass spectroscopy (Metabolon, Inc., N.C.). Metabolite‐vitamin D associations were modeled using linear regression. A statistically significant (p<0.05) change in beta‐estimates per 1 standard deviation (SD) increment was seen for 117 metabolites, the majority of which were lipids, along with 26 amino acids, 10 xenobiotics, seven peptides, six cofactors or vitamins, and four carbohydrate metabolites. Six lipid metabolites were significant at the Bonferroni corrected threshold of p < 0.000053, including 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF) (beta=0.42/1 SD increment), stearoyl‐arachidonoyl‐glycerophosphoethanolamine (GPPE) (beta =−0.36/1 SD), stearoyl‐linoleoyl‐GPPE (beta = −0.35/1 SD), erucoyl sphingomyelin (beta = 0.32/1 SD), eicosapentaenoate (beta=0.24/1 SD) and docosahexaenoate (beta=0.21/1 SD). The identification of these metabolites may provide insights into the role of vitamin D in human health. Support or Funding Information Research support: Intramural Research Program of the National Cancer Institute, NIH.